scholarly journals The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy

2017 ◽  
Vol 2017 ◽  
pp. 1-12 ◽  
Author(s):  
Janina Bruening ◽  
Bettina Weigel ◽  
Gisa Gerold

The human interferon (IFN) response is a key innate immune mechanism to fight virus infection. IFNs are host-encoded secreted proteins, which induce IFN-stimulated genes (ISGs) with antiviral properties. Among the three classes of IFNs, type III IFNs, also called IFN lambdas (IFNLs), are an essential component of the innate immune response to hepatitis C virus (HCV). In particular, human polymorphisms in IFNL gene loci correlate with hepatitis C disease progression and with treatment response. To date, the underlying mechanisms remain mostly elusive; however it seems clear that viral infection of the liver induces IFNL responses. As IFNL receptors show a more restricted tissue expression than receptors for other classes of IFNs, IFNL treatment has reduced side effects compared to the classical type I IFN treatment. In HCV therapy, however, IFNL will likely not play an important role as highly effective direct acting antivirals (DAA) exist. Here, we will review our current knowledge on IFNL gene expression, protein properties, signaling, ISG induction, and its implications on HCV infection and treatment. Finally, we will discuss the lessons learnt from the HCV and IFNL field for virus infections beyond hepatitis C.

2005 ◽  
Vol 86 (6) ◽  
pp. 1589-1596 ◽  
Author(s):  
Nathan W. Bartlett ◽  
Karen Buttigieg ◽  
Sergei V. Kotenko ◽  
Geoffrey L. Smith

Human interferon lambdas (IFN-λs) (type III IFNs) exhibit antiviral activity in vitro by binding to a receptor complex distinct from that used by type I and type II IFNs, and subsequent signalling through the Janus kinase signal transducers and activators of transcription (STAT) pathway. However, evidence for a function of type III IFNs during virus infection in vivo is lacking. Here, the expression of murine IFN-λs by recombinant vaccinia virus (VACV) is described and these proteins are shown to have potent antiviral activity in vivo. VACV expressing murine IFN-λ2 (vIFN-λ2) and IFN-λ3 (vIFN-λ3) showed normal growth in tissue culture and expressed N-glycosylated IFN-λ in infected cell extracts and culture supernatants. The role that murine IFN-λs play during virus infection was assessed in two different mouse models. vIFN-λ2 and vIFN-λ3 were avirulent for mice infected intranasally and induced no signs of illness or weight loss, in contrast to control viruses. Attenuation of vIFN-λ2 was associated with increases in lymphocytes in bronchial alveolar lavages and CD4+ T cells in total-lung lymphocyte preparations. In addition, vIFN-λ2 was cleared more rapidly from infected lungs and, in contrast to control viruses, did not disseminate to the brain. Expression of IFN-λ2 also attenuated VACV in an intradermal-infection model, characterized by a delay in lesion onset and reduced lesion size. Thus, by characterizing murine IFN-λs within a mouse infection model, the potent antiviral and immunostimulatory activity of IFN-λs in response to poxvirus infection has been demonstrated.


1998 ◽  
Vol 28 ◽  
pp. 97
Author(s):  
Y. Castelruiz ◽  
E. Larrea ◽  
A. Alberdi ◽  
P. Bova ◽  
M.P. Civeira ◽  
...  

Hepatology ◽  
2014 ◽  
Vol 60 (4) ◽  
pp. 1170-1179 ◽  
Author(s):  
Benjamin Israelow ◽  
Christopher M. Narbus ◽  
Marion Sourisseau ◽  
Matthew J. Evans

2013 ◽  
Vol 67 (4) ◽  
pp. 345
Author(s):  
Karen Fitzmaurice ◽  
Jacob Hurst ◽  
Megan Dring ◽  
Clair Gardiner ◽  
Paul Klenerman

Sign in / Sign up

Export Citation Format

Share Document